

ASX Announcement | 17 September 2020 Noxopharm Limited (ASX:NOX)

Notification of Date of 2020 Annual General Meeting

Sydney, 17 September 2020: Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) advises that the Company's 2020 Annual General Meeting (AGM) will be held on Tuesday 17 November 2020 at 2.00 pm AEDT.

Further to Listing Rules 3.13.1 and 14.3 and clause 60 of the Company's constitution, nominations for election of directors at the AGM must be received not less than 30 Business Days before the meeting, being no later than Tuesday 6 October 2020.

The location of the AGM is subject to COVID-19 restrictions, including regulatory requirements. Further details, including any hybrid or virtual meeting arrangements, will be confirmed closer to the AGM. Following formalities, Noxopharm executives will provide a corporate and clinical update on the significant progress of the Company this year.

The Company is encouraging shareholders to elect to receive all shareholder communications by email. To achieve this, shareholders are encouraged to contact the share registry, Automic Group, via the details below, to provide their email address:

• Visit: www.automicgroup.com.au

• Email: hello@automic.com.au

Telephone: (Within Australia) 1300 288 664 (Outside Australia) +61 2 9698 5414

-ENDS-

Graham Kelly, CEO, has approved the release of this document to the market on behalf of the Board of Directors.

About Noxopharm

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and septic shock.

Veyonda® is the Company's first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions — inhibition of sphingosine kinase and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immuno-oncology functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiotherapy and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, also contributing to an anti-cancer action, but also potentially blocking sepsis.

Noxopharm also is the major shareholder of US biotechnology company Nyrada Inc (ASX:NYR).

To learn more, please visit: <u>noxopharm.com</u>



Investor & Corporate enquiries:

Prue Kelly M: 0459 022 445

E: info@noxopharm.com

Media Enquiries

Julia Maguire The Capital Network

E: julia@thecapitalnetwork.com.au

T: +61 2 8999 3699

Company Secretary:

David Franks

T: +61 2 8072 1400

E: David.Franks@automicgroup.com.au

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.